Home › Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA
 

Keywords :   


Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

2014-11-25 16:58:52| Biotech - Topix.net

Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy . SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.

Tags: with study children phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
More »